Meeting
2022 ASCO Annual Meeting
Phase II study of the combination of daratumumab, ixazomib, pomalidomide, and dexamethasone as salvage therapy in relapsed/refractory multiple myeloma: Stage 2 interim results.
Authors
Anupama Deepa Kumar
University of California-San Diego, La Jolla, CA
Anupama Deepa Kumar , Michelle Padilla , Lin Liu , Minya Pu , Emily Pittman , Dimitrios Tzachanis , Sarah Marie Larson , Nina Shah , Carolyn M. Mulroney , Edward David Ball , Aaron Seth Rosenberg , Caitlin Costello
Disclaimer
This material on this page is ©2024 American Society of Clinical Oncology, all rights reserved. Licensing available upon request. For more information, please contact licensing@asco.org
Poster Details
Session Type
Poster Session
Session Title
Hematologic Malignancies—Plasma Cell Dyscrasia
Track
Hematologic Malignancies
Sub Track
Multiple Myeloma
Clinical Trial Registration Number
NCT03590652
Citation
J Clin Oncol 40, 2022 (suppl 16; abstr 8041)
DOI
10.1200/JCO.2022.40.16_suppl.8041
Abstract #
8041
Poster Bd #
465
Abstract Disclosures
Similar Posters
Poster
2022 ASCO Annual Meeting
MagnetisMM-5: An open-label, multicenter, randomized phase 3 study of elranatamab as monotherapy and in combination with daratumumab in patients with relapsed/refractory multiple myeloma.
First Author: Sebastian Grosicki
Poster
2021 ASCO Annual Meeting
Comparison of outcomes with ciltacabtagene autoleucel (cilta-cel) in CARTITUDE-1 versus real-world standard of care (RW SOC) for patients (pts) with triple-class exposed relapsed/refractory multiple myeloma (RRMM).
First Author: Thomas G. Martin
Poster
2023 ASCO Annual Meeting
Ixazomib and daratumumab without dexamethasone (I-Dara) in elderly frail patients with RRMM: Results of the multicenter phase 2 study (IFM 2018-02) of the Intergroupe Francophone du Myélome (IFM).
First Author: Cyrille Touzeau
Poster
2023 ASCO Annual Meeting
EXCALIBER-RRMM: A phase 3, two-stage study of iberdomide, daratumumab, and dexamethasone (IberDd) versus daratumumab, bortezomib, and dexamethasone (DVd) in patients (pts) with relapsed/refractory multiple myeloma (RRMM).
First Author: Sagar Lonial